MA39485A - Méthode de traitement de la dépression et du trouble dépressif majeur - Google Patents
Méthode de traitement de la dépression et du trouble dépressif majeurInfo
- Publication number
- MA39485A MA39485A MA039485A MA39485A MA39485A MA 39485 A MA39485 A MA 39485A MA 039485 A MA039485 A MA 039485A MA 39485 A MA39485 A MA 39485A MA 39485 A MA39485 A MA 39485A
- Authority
- MA
- Morocco
- Prior art keywords
- depressive disorder
- major depressive
- treating depression
- depression
- treating
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948529P | 2014-03-05 | 2014-03-05 | |
| US201462061417P | 2014-10-08 | 2014-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39485A true MA39485A (fr) | 2015-09-11 |
Family
ID=54055831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039485A MA39485A (fr) | 2014-03-05 | 2015-03-04 | Méthode de traitement de la dépression et du trouble dépressif majeur |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170137880A1 (enExample) |
| EP (1) | EP3114239A4 (enExample) |
| JP (1) | JP2017512204A (enExample) |
| KR (1) | KR20160127126A (enExample) |
| CN (1) | CN106536751A (enExample) |
| AU (1) | AU2015227296A1 (enExample) |
| CA (1) | CA2940683A1 (enExample) |
| IL (1) | IL247379A0 (enExample) |
| MA (1) | MA39485A (enExample) |
| MX (1) | MX2016011384A (enExample) |
| RU (1) | RU2016138574A (enExample) |
| WO (1) | WO2015134585A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (en) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Method for treating crohn's disease |
| PL3528811T3 (pl) * | 2017-03-30 | 2022-01-10 | Rundle Research, LLC | Wortioksetyna i inhibitory mao do leczenia depresji |
| EP3909600A1 (en) * | 2020-05-12 | 2021-11-17 | International Centre For Genetic Engineering And Biotechnology - ICGEB | Emid2 protein as anti-cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2439201B1 (en) * | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| EP2581454B1 (en) * | 2008-01-17 | 2015-09-16 | Suregene LLC | Genetic markers of mental illness |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2622101A4 (en) * | 2010-10-01 | 2014-04-02 | Rigshospitalet | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
| US9243464B2 (en) * | 2011-02-10 | 2016-01-26 | Baker Hughes Incorporated | Flow control device and methods for using same |
| WO2012109565A1 (en) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Genetic identification of response to antidepressant medications |
| AU2012340015B2 (en) * | 2011-11-14 | 2017-09-21 | Alfasigma S.P.A. | Assays for selecting a treatment regimen for a subject with depression and methods for treatment |
-
2015
- 2015-03-04 CN CN201580023401.1A patent/CN106536751A/zh active Pending
- 2015-03-04 MX MX2016011384A patent/MX2016011384A/es unknown
- 2015-03-04 JP JP2016554883A patent/JP2017512204A/ja active Pending
- 2015-03-04 WO PCT/US2015/018701 patent/WO2015134585A1/en not_active Ceased
- 2015-03-04 EP EP15758563.9A patent/EP3114239A4/en not_active Withdrawn
- 2015-03-04 CA CA2940683A patent/CA2940683A1/en not_active Abandoned
- 2015-03-04 US US15/123,072 patent/US20170137880A1/en not_active Abandoned
- 2015-03-04 MA MA039485A patent/MA39485A/fr unknown
- 2015-03-04 RU RU2016138574A patent/RU2016138574A/ru not_active Application Discontinuation
- 2015-03-04 AU AU2015227296A patent/AU2015227296A1/en not_active Abandoned
- 2015-03-04 KR KR1020167027125A patent/KR20160127126A/ko not_active Withdrawn
-
2016
- 2016-08-21 IL IL247379A patent/IL247379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3114239A1 (en) | 2017-01-11 |
| KR20160127126A (ko) | 2016-11-02 |
| RU2016138574A (ru) | 2018-04-06 |
| CN106536751A (zh) | 2017-03-22 |
| WO2015134585A1 (en) | 2015-09-11 |
| MX2016011384A (es) | 2017-05-01 |
| JP2017512204A (ja) | 2017-05-18 |
| CA2940683A1 (en) | 2015-09-11 |
| US20170137880A1 (en) | 2017-05-18 |
| RU2016138574A3 (enExample) | 2018-10-12 |
| IL247379A0 (en) | 2016-11-30 |
| AU2015227296A1 (en) | 2016-09-08 |
| EP3114239A4 (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| IL246678A0 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| EP3463350A4 (en) | METHOD FOR TREATING LIVER FIBROSE | |
| EP3341080A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3288383A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3380121A4 (en) | METHOD FOR THE TREATMENT OF EYE DISEASES | |
| IL249071B (en) | Bleaching and shive reduction process for non-wood fibers | |
| EP3423488A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3391873A4 (en) | PROCESS AND KIT FOR HAIR PROCESSING | |
| LT3174394T (lt) | Augalo inokuliavimo būdas | |
| EP3522934A4 (en) | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES | |
| EP3375440A4 (en) | METHOD FOR THE TREATMENT OF MUCOSITIS | |
| EP3389634A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3405203A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3630732A4 (en) | Method and molecules | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| EP3440112A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| DK3233071T3 (da) | Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme | |
| EP3313417A4 (en) | METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3331499A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF METABOLISM DISEASES | |
| EP3389652A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| EP3448365A4 (en) | METHOD FOR TREATING CONSTRUCTION | |
| MA41636A (fr) | Méthode de traitement de la cholangite sclérosante primitive |